Capsules of 9-cis-retinoic acid have moderate activity in the treatment of AIDS-related Kaposi sarcoma, say researchers in the United States. Patient responses are durable, but higher doses have major toxic effects, limiting the suitability of 9-cis-retinoic acid, report the researchers in Seattle, Washington, Tampa, Florida, Pittsburgh, Pennsylvania, and Beverly Hills and San Diego, California.
They assessed the safety, dose tolerance and anti-tumour effects of 9-cis-retinoic acid for AIDS-related Kaposi sarcoma in a phase 2, open-label clinical trial. Fifty seven men received oral doses starting at 60 mg/m² daily and rising in 40 mg. increments every two weeks up to 140 mg/m² daily.
The investigators evaluated safety by adverse events, physical examination, laboratory test abnormalities, treatment-limiting toxic effects and reasons for early withdrawal. Response, defined as 50% improvement, was gauged by overall Kaposi sarcoma response and by area and height from six index lesions at baseline….
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!